The use of immune-related cancer treatments has skyrocketed in recent years, dramatically transforming the outcomes and survival rates for many patients. With increasing numbers of people eligible for immunotherapy, pharmacists need to understand the toxicities associated with these therapies and how they can best support patients throughout the course of their treatment.
In this episode of The PJ Pod, Caitlin Killen, assistant clinical editor, and Alex Clabburn, senior editor, enlist the help of two experts to explore what the rise in immunotherapy treatment means for the ongoing care of cancer patients, including practical aspects of managing side effects, how to support and educate patients and what to do in the event of suspected toxicities.
Many thanks to Dharmisha Chauhan, lead genomic clinical pharmacist for North Thames Genomic Medicine Service Alliance and specialist oncology pharmacist at The Royal Marsden NHS Foundation Trust, and Stuart Evans, cancer pharmacist at South West Wales Cancer Centre at Singleton Hospital and Swansea Bay University Health Board, for their expertise.
This episode was produced by Geoff Marsh.
- Bladder cancer: management (May 2022, The Pharmaceutical Journal)
- Renal cancer: management (June 2022, The Pharmaceutical Journal)
- Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response (December 2021, Science)
- Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. (January 2019, Oncologist)
- Impact of acetaminophen on the efficacy of immunotherapy in patients with cancer (June 2022, Journal of Clinical Oncology)
- Pneumocystis pneumonia (July 2022, BNF)
- Immuno-oncology agents for cancer therapy (May 2020, The Pharmaceutical Journal)
- Immune checkpoint inhibitors in cancer: pharmacology and toxicities (May 2018, The Pharmaceutical Journal)